GAD1 and type 1 diabetes mellitus: Vaccination with subcutaneous application of a recombinant GAD molecule (20) mcg GAD-alum) was tested both inindividuals with classic T1D aged 10 to 20 years, and in patients with Latent AutoimmuneDiabetes of Adults (LADA).